Literature DB >> 15812764

Review of sterile, postoperative, anterior segment inflammation following cataract extraction and intraocular lens implantation.

A H Bilge1, U Aykan, T Akin, U Unsal.   

Abstract

PURPOSE: To evaluate unexpected, acute intraocular anterior segment inflammation following uneventful cataract extraction by phacoemulsification and foldable posterior chamber intraocular lens (PCIOL) implantation.
METHODS: This retrospective study evaluated five cases of postoperative inflammation that occurred after cataract extraction with foldable PCIOL implantation. Medical records were reviewed to analyze the unexplained postoperative inflammation.
RESULTS: The five patients who developed inflammatory activity during the postoperative period responded well to corticosteroid treatment. Toxic maculopathy developed in one patient after aggressive antibacterial therapy. Vitrectomy was performed for one patient with prolonged vitreal inflammatory activity.
CONCLUSIONS: Noninfectious endophthalmitis developing upon surgery may be caused by a multifactorial process or an interindividual variable response to a common factor as a hypersensitivity reaction. It should be remembered in inflammatory cases after surgery in order to prevent the toxic, irreversible side effects of bacterial endophthalmitis treatment.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15812764     DOI: 10.1177/112067210501500208

Source DB:  PubMed          Journal:  Eur J Ophthalmol        ISSN: 1120-6721            Impact factor:   2.597


  2 in total

1.  The role of Dexamethasone in clinical pharmaceutical treatment for patients with cataract surgery.

Authors:  Gaokun Zhang; Shuang Liu; Lieying Yang; Yanqing Li
Journal:  Exp Ther Med       Date:  2017-12-15       Impact factor: 2.447

2.  Comparison of the keratometric corneal astigmatism and refractive astigmatism after phacoemulsification and foldable intraocular lens implantation.

Authors:  Ali Sharifi; Leila Sharifi; Afsaneh Morteza
Journal:  Int Ophthalmol       Date:  2012-06-09       Impact factor: 2.031

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.